세계 특발성 막성 신증(IMN) 시장 규모는 2024년부터 2031년까지 예측 기간 동안 연평균 8.83%의 CAGR로 2023년 2억 140만 달러에서 2031년에는 3억 9,618만 달러 규모로 성장할 것으로 예상됩니다.
IMN에 대한 인식이 높아지고 진단 솔루션의 경제성을 높이기 위한 정부의 노력은 시장에 유리한 성장 기회를 제공하고 있습니다. 이에 따라 IMN 환자의 병용요법 동향을 파악하기 위한 연구 활동이 점점 더 활발해지고 있으며, 이는 중요한 시장 동향으로 작용하고 있습니다. 고령화 인구의 증가, 좌식 생활습관의 증가, 신장 질환의 발생률 증가로 인해 시장 수요는 더욱 증가하고 있습니다.
정부 차원의 노력 강화가 시장 성장을 뒷받침
R&D 활동을 지원하는 다양한 정부 기관의 노력이 증가함에 따라 시장에 유리한 성장 기회를 제공하고 있으며, IMN의 다양한 환자에서 약물의 효능을 밝히기 위해 다양한 연구가 진행되고 있습니다.
R&D 활동의 활성화가 시장 발전을 촉진한다
R&D 활동은 혁신 촉진, 신제품 개발 촉진, 기존 제품의 유효성 향상 등 다양한 이점이 있습니다. 또한, 연구자들은 병용요법의 효과에 대한 연구도 진행하고 있습니다. 중국 베이징의 Peking Union Medical College Hospital은 IMN 치료에 있어 RTX와 사이클로스포린 병용요법이 RTX 단독요법보다 더 효과적인지 알아보기 위한 중재연구를 진행하고 있습니다. 리툭시맙(RTX) 또는 사이클로포스파미드와 부신피질스테로이드의 병용요법이 IMN의 1차 면역억제요법으로 사용되고 있습니다. 그러나 리툭시맙 단독요법의 장기 관해율은 약 60%에 불과합니다. 사이클로스포린과 RTX는 포도세포와 면역체계에 대한 작용이 다르고 작용 시간도 다르기 때문에 특발성 막성 신증 치료에 시너지 효과를 기대할 수 있습니다.
북미가 큰 시장 점유율을 차지한다
예측 기간 동안 북미 지역이 시장에서 큰 비중을 차지할 것으로 예상됩니다. 이러한 성장은 다양한 주요 업체들의 강력한 존재감과 이 지역의 다양한 연구 기관들의 연구 활동 증가에 기인합니다. 미국 NIAID는 IMN 환자를 대상으로 리툭시맙과 베림맙의 정맥 투여를 통한 완전관해 유도 효과를 리툭시맙 단독 투여와 비교하는 연구를 진행하고 있습니다. 이 중재연구는 리툭시맙과 베림맙 병용요법이 리툭시맙 단독요법 대비 특발성 막성 신증 환자의 신장에 대한 면역공격을 효과적으로 차단할 수 있는지를 연구하고 있습니다.
세계 특발성 막성 신증(IMN) 시장을 조사했으며, 시장 정의와 개요, 시장 규모 추이와 예측, 각종 분류 및 지역별 상세 분석, 산업 구조, 시장 성장에 영향을 미치는 요인 분석, 사례 연구, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
Global idiopathic membranous nephropathy (IMN) market is projected to witness a CAGR of 8.83% during the forecast period 2024-2031F, growing from USD 201.4 million in 2023 to USD 396.18 million in 2031. The growing awareness about idiopathic membranous nephropathy and rising government efforts to increase the affordability of diagnostic solutions are providing lucrative growth opportunities to the market. In line with this, research activities are increasingly being conducted to determine the effects of combination therapy in patients with idiopathic membranous nephropathy, which is acting as a crucial market trend. The market demand is further driven by an increasing aging population, growing adoption of a sedentary lifestyle, and rising rate of renal diseases.
Increasing research activities by different research institutions to understand the effects of different treatments in patients with idiopathic membranous nephropathy is further supporting the market expansion. For instance, Beijing Friendship Hospital is conducting an interventional, randomized, open controlled study to understand the influence of various treatment schemes on the cognitive status of patients suffering from idiopathic membranous nephropathy. The exploration of the possible pathophysiological mechanism is expected to be conducted with the help of brain magnetic resonance imaging technology. The study aims to provide a theoretical basis for enhanced prevention of cognitive impairment and clinical treatment scheme selection and more information about the clinical cognitive status of idiopathic membranous nephropathy. The study is expected to conclude in 2025.
Rising Government Efforts Support Market Growth
Increasing efforts by various government institutes to support research and development activities are providing lucrative growth opportunities to the market. Different research studies are being conducted to determine the efficacy of drugs in different patients with idiopathic membranous nephropathy. The National Natural Science Foundation of China is supporting different research activities for treating idiopathic membranous nephropathy. Various studies have been conducted to demonstrate the efficacy of drugs in patients suffering from idiopathic membranous nephropathy with high or moderate proteinuria, however, systemic comparison has yet to be confirmed. Therefore, a network meta-analysis was performed for comparing the efficacy of idiopathic membranous nephropathy treatments in patients with high and moderate proteinuria, while comparing the risk of adverse events with idiopathic membranous nephropathy regimens.
Increasing Research and Development Activities are Boosting the Market Expansion
Research and development activities offer various benefits, including facilitation of innovation and accelerated development of new products as well as aid in improving the efficacy of existing products. They also allow researchers to study the effects of combination therapy. For instance, Peking Union Medical College Hospital, Beijing, China is conducting an interventional study to determine whether RTX combined with cyclosporine is more effective than RTX alone for treating idiopathic membranous nephropathy. The first-line immunosuppressive therapy of idiopathic membranous nephropathy includes Rituximab (RTX) or cyclophosphamide in combination with corticosteroids due to their superior safety profile. However, the long-term remission rate of Rituximab monotherapy is about 60%. Cyclosporin and RTX are expected to have a synergistic effect for treating idiopathic membranous nephropathy as they have different effects on podocytes and the immune system and different time of action.
North America Accounts for Significant Market Share
North America is expected to account for a significant share of the market over the forecast period. This growth can be attributed to the strong presence of various leading market players and increasing research activities by different research organizations in the region. For instance, the National Institute of Allergy and Infectious Diseases (NIAID) is conducting a study to evaluate the effectiveness of intravenous rituximab and belimumab at inducing complete remission as compared to just rituximab in patients suffering from idiopathic membranous nephropathy. In this interventional study, researchers will evaluate if treating idiopathic membranous nephropathy in combination with rituximab and belimumab will effectively block the immune attacks on kidney in comparison to rituximab alone. Rituximab works by decreasing B cells, they are known to have a role in membranous nephropathy. Upon the removal of these cells, the disease might become less active or even completely inactive. Belimumab works by changing the type of new B cells produced in the body and decreasing the B cells. Belimumab has received approval from the Food and Drug Administration (FDA) for treating systemic lupus erythematosus, whereas rituximab is approved for treating vasculitis, rheumatoid arthritis, and some types of cancer. Treating membranous nephropathy with a combination of rituximab and belimumab has previously not been studied, however the combination has been tested for treating other autoimmune diseases. The study is expected to reach completion in 2030.
Cyclophosphamide Expected to Witness Significant Expansion
Recent studies have shown that alternating glucocorticoid-cyclophosphamide is superior to rituximab for proteinuria remission. RI-CYCLO and STARMEN confirmed the efficacy of glucocorticoid-cyclophosphamide in patients suffering from high-risk membranous nephropathy. For treating high-risk patients, the 2021 KDIGO guidelines recommend initiation of immunosuppressive treatments with cyclophosphamide associated with steroids, calcineurin, or RTX. The only recommended option for treatment in very high-risk patients is corticosteroids plus cyclophosphamide. Potential new strategies for the treatment of idiopathic membranous nephropathy include the utilization of an induction phase with intravenous cyclophosphamide on a monthly basis or a combination of RTX with low-dose cyclophosphamide. These strategies showcased encouraging immunological remission and clinical results, with excellent safety profile.
Hospitals Account for Significant Market Share
Hospitals are expected to account for a significant market share as some patients often face life threatening and severe nephrotic syndrome even while the excretory renal functions are working normally. Various medical college hospitals are conducting studies to understand the effects of different immunosuppressive therapies in patients suffering from idiopathic membranous nephropathy, which is expected to create positive market opportunities. For instance, Peking Union Medical College Hospital, Beijing, China, is conducting an interventional study for comparing the twenty-four-month remissions in idiopathic membranous nephropathy by different immunosuppressive therapies. The investigators designed this study for comparing the efficacy of corticosteroids plus cyclophosphamide with rituximab in treating idiopathic membranous nephropathy. The study is estimated to reach completion in 2027.
Future Market Scenario (2024 - 2031F)
Different research activities are underway in various regions across the globe for determining the tolerability, safety, and efficacy of different treatments for idiopathic membranous nephropathy. For instance, Nagoya University, Nagoya, Japan is conducting an interventional study to confirm the safety and efficacy of intravenous administration of rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome. The clinical study is going to be double-blind, randomized, multi-center, and placebo controlled and is estimated to reach completion in December 2026. Furthermore, various biotech companies, including SynAct Pharma Aps, are also conducting different studies to evaluate the efficacy and pharmacokinetic effects of different treatments in patients with idiopathic membranous nephropathy.
Key Players Landscape and Outlook
Key participants in the idiopathic membranous nephropathy (IMN) market include Pfizer, Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Astellas Pharma Inc., and GlaxoSmithKline. The market is expected to witness significant growth over the forecast period due to rising research and development activities by different market players and the conduct of several clinical trials.
Novartis AG, one of the leading pharmaceutical corporations, received positive results for their phase 3 trials for targeted factor B inhibitor iptacopan. The company plans on initiating discussions with the FDA to receive accelerated approval for iptacopan, whose target indications include idiopathic membranous nephropathy, C3 glomerulopathy, and atypical haemolytic uraemic syndrome.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work